TwinBeech Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$170K Buy
+14,516
New +$237K 0.04% 362
2025
Q4
– Sell
-43,735
Closed -$314K – 758
2025
Q3
$314K Buy
+43,735
New +$2.28M 0.01% 466
2024
Q3
– Sell
-58,552
Closed -$2.57M – 803
2024
Q2
$2.57M Buy
+58,552
New +$2.48M 0.05% 306

Other funds holding MLTX

TwinBeech Capital's MLTX Position: Q3 2026 in Review

TwinBeech Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 14,516 shares worth $170K. The stake represents 0.04% of the portfolio and ranks #362 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in MLTX as recently as Q3 2025.

TwinBeech Capital first reported a position in MLTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $2.57M in Q2 2024. 167 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • TwinBeech Capital held 14,516 shares of MoonLake Immunotherapeutics worth $170K as of Q3 2026.
  • MoonLake Immunotherapeutics was a new TwinBeech Capital position in Q3 2026.
  • MoonLake Immunotherapeutics made up 0.04% of TwinBeech Capital's portfolio in Q3 2026, its #362 holding.
  • TwinBeech Capital first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 3 quarters since.
  • TwinBeech Capital's MoonLake Immunotherapeutics position peaked at $2.57M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.